You have 9 free searches left this month | for more free features.

Evaluate the Effect of Genasense on the Efficacy/Safety of Rituximab/Fludarabine Treatment in Untreated Subjects With Chronic Lymphocyctic Leukemia

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial (Nemtabrutinib, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Leukemia
  • (no location specified)
Nov 30, 2022

Untreated Chronic Lymphocytic Leukemia Trial in Worldwide (Acalabrutinib, Rituximab, Chlorambucil)

Recruiting
  • Untreated Chronic Lymphocytic Leukemia
  • Beijing, China
  • +50 more
Sep 26, 2022

Chronic Lymphocytic Leukemia (CLL) Trial in Worldwide (Obinutuzumab, Venetoclax, Fludarabine)

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Aurora, Colorado
  • +55 more
Jan 30, 2023

Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (drug, other, biological)

Active, not recruiting
  • Anemia
  • +2 more
  • Birmingham, Alabama
  • +795 more
Jan 28, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed Trial in Tianjin (Zanubrutinib, Fludarabine,

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Zanubrutinib, Fludarabine, cyclophosphamide and rituximab
  • Zanubrutinib, bendamustine, rituximab
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Mar 18, 2022

Chronic Lymphocytic Leukemia Trial in Worldwide (Acalabrutinib, Venetoclax, Chemoimmunotherapy)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Fountain Valley, California
  • +201 more
Jan 16, 2023

Leukemia, Lymphocytic, Chronic Trial in Germany (ibrutinib, obinutuzumab, venetoclax)

Completed
  • Leukemia, Lymphocytic, Chronic
  • Dresden, Germany
  • +10 more
Jan 13, 2023

Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia Trial in Xuzhou (allogenic CD19-CAR-NK cells)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • allogenic CD19-CAR-NK cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 11, 2023

Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia Trial in Tianjin (LILRB4 STAR-T cells injection)

Not yet recruiting
  • Acute Myelogenous Leukemia
  • Chronic Myelomonocytic Leukemia
  • LILRB4 STAR-T cells injection
  • Tianjin, Tianjin, China
  • +1 more
Feb 12, 2023

Chronic Lymphocytic Leukemia, Leukemia Trial in United States (Ibrutinib, Fludarabine, Cyclophosphamide)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Leukemia
  • Coral Gables, Florida
  • +8 more
Sep 28, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in China (ICP-022, Chlorambucil, Rituximab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Bengbu, Anhui, China
  • +55 more
Mar 25, 2022

B-cell Lymphoma, B-cell Acute Lymphoblastic Leukemia Trial in Hangzhou (QN-019a, Rituximab, Cyclophosphamid)

Recruiting
  • B-cell Lymphoma
  • B-cell Acute Lymphoblastic Leukemia
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital of Medical College of Zhejiang Uni
May 17, 2022

Chronic Lymphocytic Leukemia Trial (Acalabrutinib, Obinutuzumab)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • (no location specified)
Jul 10, 2023

Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia Trial in

Active, not recruiting
  • Stage I Chronic Lymphocytic Leukemia
  • +3 more
  • Scottsdale, Arizona
  • +363 more
Dec 30, 2022

Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin Trial in Madison (Bendamustine, Rituximab, Lenalidomide)

Completed
  • Lymphoid Leukemia
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin
Jan 30, 2023

Chronic Lymphocytic Leukemia Trial in San Diego (ISF35)

Completed
  • Chronic Lymphocytic Leukemia
  • ISF35
  • San Diego, California
    University of California, San Diego Moores Cancer Center
Sep 15, 2021

Chronic Lymphocytic Leukemia Trial in Boston (IPI-145, Fludarabine, Cyclophosphamide)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Boston, Massachusetts
  • +1 more
Mar 10, 2022

Relapsed DLBCL, Refractory DLBCL Trial in Hackensack (ABT-199, Ibrutinib, Rituximab)

Active, not recruiting
  • Relapsed Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Hackensack, New Jersey
    John Theurer Cancer Center at Hackensack University Medical Cent
Oct 7, 2022

Chronic Lymphocytic Leukemia Trial in Cologne (lenalidomide, Placebo)

Completed
  • Chronic Lymphocytic Leukemia
  • Cologne, Germany
  • +1 more
Dec 16, 2021

Chronic Lymphocytic Leukemia Trial in Cologne (Ibrutinib, Placebo)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Cologne, Germany
    German CLL Study Group
Dec 16, 2021

B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Unspecified Trial in Guangzhou, Guanzhou (CD19 CAR T-Cell(CAT19T2))

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B-Cell Lymphoma, Unspecified
  • CD19 CAR T-Cell(CAT19T2)
  • Guangzhou, Guangdong, China
  • +1 more
Nov 4, 2022

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic

Active, not recruiting
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 2, 2022

Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Fairway, Houston (SC291)

Recruiting
  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Fairway, Kansas
  • +1 more
May 30, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial in Columbus (acalabrutinib,

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Columbus, Ohio
    Research Site
Mar 11, 2022

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Houston (Rituximab, Zanubrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022